Erythropoietin
- Generic Name
- Erythropoietin
- Brand Names
- Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11096-26-7
- Unique Ingredient Identifier
- 64FS3BFH5W
- Background
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...
- Indication
用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。
- Associated Conditions
- Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine
- Associated Therapies
- -
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 132
- Registration Number
- NCT01718379
- Locations
- 🇲🇨
centre hopitalier princesse Grace, Monaco, Monaco
🇫🇷Hopital Saint Antoine, Paris, France
🇫🇷CH de la Cote Basque, Bayonne, France
Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 92
- Registration Number
- NCT01695759
- Locations
- 🇧🇷
Hospital de Ensino Padre Anchieta, São Bernardo do Campo, São Paulo, Brazil
🇧🇷Fundação Universitária de Caxias do Sul - Instituto de Pesquisa Clínica para Estudos Multicêntricos, Caxias do Sul, Rio Grande Do Sul, Brazil
🇧🇷Clínica Senhor do Bomfim Ltda, Feira de Santana, Bahia, Brazil
Erythropoietin in the Prevention of Acute Mountain Sickness
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2013-03-19
- Lead Sponsor
- University of Ulsan
- Target Recruit Count
- 39
- Registration Number
- NCT01665781
- Locations
- 🇰🇷
Soon Bae Kim, M.D., Ph.D., Seoul, Korea, Republic of
Erythropoietin Therapy for Children With Cerebral Palsy
- Conditions
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Bundang CHA Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT01650415
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- MinYoung Kim, M.D.
- Target Recruit Count
- 11
- Registration Number
- NCT01586052
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
Erythropoietin and Platelet Activation Markers
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 12
- Registration Number
- NCT01392612
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Prevention of Contrast Induced Nephropathy by Erythropoietin
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Western Galilee Hospital-Nahariya
- Target Recruit Count
- 142
- Registration Number
- NCT01364402
- Locations
- 🇮🇱
Western Galilee Hospital, Nahariya, Israel
Blood Sparing Strategies: Single Shot High Dose Erythropoietin Two Days Before Heart Surgery
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Cardiochirurgia E.H.
- Target Recruit Count
- 600
- Registration Number
- NCT01265680
- Locations
- 🇮🇹
European Hospital, Rome, Italy
The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- NICHD Neonatal Research Network
- Target Recruit Count
- 318
- Registration Number
- NCT01203514
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Harvard University, Cambridge, Massachusetts, United States
A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT01170078
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.